{"nctId":"NCT00414973","briefTitle":"A Study for Patients With Osteoporosis","startDateStruct":{"date":"2006-12"},"conditions":["Osteoporosis"],"count":364,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: Teriparatide"]},{"label":"B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Salmon Calcitonin"]}],"interventions":[{"name":"Teriparatide","otherNames":["LY333334","Forteo","Forsteo"]},{"name":"Salmon Calcitonin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of osteoporosis\n* No other severe disabling conditions\n* Should have at least 1 vertebral or non-vertebral prevalent fracture, and bone mineral density T-score should be less than -2.5\n* Ambulatory\n* Men (aged 40 to 85 years) or postmenopausal women (aged 55 to 85 years)\n\nExclusion Criteria:\n\n* History of a disease that affects bone metabolism\n* History of treatment with any drug that may significantly affect bone metabolism\n* History or presence of liver disease\n* History or presence of kidney disease\n* History of excessive alcohol drinking or drug abuse","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Change From Baseline to 24 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD), Postmenopausal Women","description":"Lumbar spine bone mineral density (milligrams per square centimeter) was measured by dual energy X-ray absorptiometry (DXA). Change = Endpoint minus baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.04","spread":"0.48"},{"groupId":"OG001","value":"1.65","spread":"0.65"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline to 24 Week Endpoint in Total Hip Bone Mineral Density (BMD), Postmenopausal Women","description":"Total hip bone mineral density (milligrams per square centimeter) was measured by dual energy X-ray absorptiometry (DXA). Change = Endpoint minus baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.53","spread":"0.44"},{"groupId":"OG001","value":"-0.62","spread":"0.59"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline to 12 Weeks and 24 Weeks in Osteocalcin, Postmenopausal Women","description":"Measures of serum osteocalcin (nanograms per milliliter). Change = Endpoint minus baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113.87","spread":"21.46"},{"groupId":"OG001","value":"-7.67","spread":"5.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137.45","spread":"36.53"},{"groupId":"OG001","value":"-10.58","spread":"8.21"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline to 24 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD), Men","description":"Lumbar spine bone mineral density (milligrams per square centimeter) was measured by dual energy X-ray absorptiometry (DXA). Change = Endpoint minus baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.01","spread":"1.20"},{"groupId":"OG001","value":"3.38","spread":"1.77"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline to 24 Week Endpoint in Total Hip Bone Mineral Density (BMD), Men","description":"Total hip bone mineral density (milligrams per square centimeter) was measured by dual energy X-ray absorptiometry (DXA). Change = Endpoint minus baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":"1.11"},{"groupId":"OG001","value":"1.34","spread":"1.54"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline to 12 Weeks and 24 Weeks in Osteocalcin, Men","description":"Measures of serum osteocalcin (nanograms per milliliter). Change = Endpoint minus baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107.27","spread":"14.88"},{"groupId":"OG001","value":"4.35","spread":"13.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.26","spread":"26.94"},{"groupId":"OG001","value":"-17.65","spread":"5.21"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8},"commonTop":["Dizziness","Muscle spasms","Pain in extremity","Nasopharyngitis","Blood alkaline phosphatase increased"]}}}